Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD160 Antibody (H7), PerCP

Catalog #:   FHB80814 Specific References (98) DATASHEET
Host species: Mouse
Isotype: IgG1, kappa
Applications: FCM
Accession: O95971
Overview

Catalog No.

FHB80814

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

PerCP

Target

Natural killer cell receptor BY55, CD160 antigen, CD160, BY55

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

O95971

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

H7

Data Image
References

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV., PMID:38728839

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV., PMID:38728839

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications., PMID:38360636

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications., PMID:38360636

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer., PMID:38290769

Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer., PMID:38290769

Linking donor-specific antibody generation with natural killer cells in antibody-mediated kidney graft rejection., PMID:37739612

Linking donor-specific antibody generation with natural killer cells in antibody-mediated kidney graft rejection., PMID:37739612

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy., PMID:37649037

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy., PMID:37649037

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment., PMID:37345056

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors., PMID:37230538

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody-mediated rejection showing a new link between adaptive and innate humoral allo-immunity., PMID:37220805

Interleukin-21 promotes Type-1 activation and cytotoxicity of CD56dimCD16bright natural killer cells during kidney allograft antibody-mediated rejection showing a new link between adaptive and innate humoral allo-immunity., PMID:37220805

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM., PMID:36081508

Realigning the LIGHT signaling network to control dysregulated inflammation., PMID:35604387

Realigning the LIGHT signaling network to control dysregulated inflammation., PMID:35604387

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing., PMID:35453072

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing., PMID:35453072

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma., PMID:35428910

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma., PMID:35428910

Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435

Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435

Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection., PMID:35336991

Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection., PMID:35336991

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome., PMID:35159987

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren's Syndrome., PMID:35159987

Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy., PMID:34888847

Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy., PMID:34888847

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity., PMID:34888843

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity., PMID:34888843

A novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer., PMID:34814366

A novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer., PMID:34814366

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms., PMID:34250086

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms., PMID:34250086

A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment., PMID:33539379

A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment., PMID:33539379

Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments., PMID:33382949

Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments., PMID:33382949

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats., PMID:33154441

A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats., PMID:33154441

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models., PMID:32363119

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models., PMID:32363119

Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes., PMID:30770415

Monocytes of Different Subsets in Complexes with Platelets in Patients with Myocardial Infarction., PMID:30300910

Monocytes of Different Subsets in Complexes with Platelets in Patients with Myocardial Infarction., PMID:30300910

[A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect]., PMID:30295284

[A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect]., PMID:30295284

Ox40 regulates the conversion and suppressive function of double-negative regulatory T cells., PMID:30268799

Ox40 regulates the conversion and suppressive function of double-negative regulatory T cells., PMID:30268799

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models., PMID:29860455

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models., PMID:29860455

ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection., PMID:29541698

ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection., PMID:29541698

Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients., PMID:29245962

Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients., PMID:29245962

A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator., PMID:29061848

A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator., PMID:29061848

Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade., PMID:28882621

Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade., PMID:28882621

Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR., PMID:28654216

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells., PMID:28588576

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells., PMID:28588576

Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection., PMID:27906829

Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection., PMID:27906829

Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier., PMID:27702550

Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier., PMID:27702550

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis., PMID:27605882

Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis., PMID:27605882

Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM., PMID:26202493

Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM., PMID:26202493

Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations., PMID:25965355

Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations., PMID:25965355

T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation., PMID:25769075

T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation., PMID:25769075

Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection., PMID:25449536

Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection., PMID:25449536

Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice., PMID:25327211

Interleukin-22 and CD160 play additive roles in the host mucosal response to Clostridium difficile infection in mice., PMID:25327211

CD160 isoforms and regulation of CD4 and CD8 T-cell responses., PMID:25179432

CD160 isoforms and regulation of CD4 and CD8 T-cell responses., PMID:25179432

[CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection]., PMID:25146744

[CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection]., PMID:25146744

CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA., PMID:24205056

CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA., PMID:24205056

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads., PMID:24204962

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads., PMID:24204962

Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors., PMID:24148617

Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors., PMID:24148617

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells., PMID:23853580

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells., PMID:23853580

CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival., PMID:23593209

CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival., PMID:23593209

Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells., PMID:23453631

Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells., PMID:23453631

Datasheet
$ 270
Product specifications
50 T 270 100 T 446

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD160 Antibody (H7), PerCP [FHB80814]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only